RARG and fibrodysplasia ossificans progressiva: These preclinical studies led to a clinical trial investigating Palovarotene, a RARγ agonist as a potential treatment for Fibrodysplasia ossificans progressiva (FOP), which is characterized by heterotopic bone formation leading to progressive loss of mobility and function.